Screener / SEC EDGAR /CIK 0000883984 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

ICU Medical Inc ICUI

Compare with peers Embed
The 10-K against last year's

149 changes: 37 added, 26 removed, 83 reworded, 3 quiet changes

10-K Feb 19, 2026 vs Feb 27, 2025

10-K 0000883984-26-000008 (Feb 19, 2026) vs 10-K 0000883984-25-000007 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

187 paragraphs · 13 new · 61 reworded · 10 gone · 10-K Feb 19, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 82 · 48% changed Every version of it
In addition, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign counterparts in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance, approval, or certification to manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance, approval, or certification; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping. For example, in February 2024, the FDA issued a final rule to amend and replace the QSR, which sets forth the FDA’s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February 2, 2026, establishes the “Quality Management System Regulation,” (“QMSR”), which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, and although our quality system is currently designed to comply with ISO standards in connection with our device certifications outside the United States, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. If we are unable to comply with QMSR, once effective, or with any other changes in the laws or regulations enforced by FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition and results of operations.
Paragraph 84 · 47% changed Every version of it
In addition, the EU landscape concerning medical devices recently evolved. evolved, and continues to undergo legislative changes. On May 26, 2021, the EU Medical Devices Regulation became applicable and repealed and replaced the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member state laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. These requirements are in active implementation and may change as the European Commission adopts additional implementing acts and considers targeted revisions to related medical device rules. In accordance with its recently extended transitional provisions, both (i) devices lawfully placed addition, on December 16, 2025, the market pursuant European Commission published a targeted revision proposal of the MDR to address structural issues, certification delays, and burdens on Small and medium-sized enterprises (“SMEs”). The proposal will enter the EU Medical Devices Directive prior to May 26, 2021 ordinary legislative procedure and (ii) legacy devices lawfully placed on the EU market after May 26, 2021 in accordance with the EU Medical Devices Regulation transitional provisions may generally continue is not expected to be made available on the market or put into service, provided that the requirements of the transitional provisions are fulfilled as may be assessed by the notified body. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the EU Medical Devices Regulation with regard to registration of economic operators and of devices, post-market surveillance, market surveillance and vigilance requirements and comply with the requirements of the notified body. adopted before 2027.
Paragraph 132 · 47% changed Every version of it
Our products have been cleared, approved or certified by the FDA, foreign regulatory authorities and notified bodies for specific indications of use. We train our marketing personnel and direct sales force to not promote our products for uses outside of the FDA-cleared or approved indications for use, known as "off-label uses." We cannot, however, prevent a physician from using our products off-label, when in the physician's independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our products off-label. Furthermore, the use of our products for indications other than those cleared or approved by the FDA or approved by any foreign body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
Paragraph 114 · 44% changed Every version of it
•analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers or patients; state laws that require device companies to comply with the industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers; and state laws related to insurance fraud in the case of claims involving private insurers.
Paragraph 99 · 44% changed Every version of it
We are subject to various federal, state and foreign laws that govern the collection, use, disclosure, retention and security of personal information, including patient health information and information that we may collect in connection with clinical trials. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our collaborators', service providers' and contractors' ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. In the U.S., numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws and regulations (e.g. Section 5 of the Federal Trade Commission Act (the "FTC Act")). For example, the privacy, security and breach notification rules promulgated under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively ("HIPAA") establish a set of national privacy and security standards for the protection of protected health information ("PHI") by health plans, health care clearinghouses and certain health care providers, called covered entities, and the business associates with whom such covered entities contract for services that involve creating, receiving, maintaining or transmitting PHI, as well as their covered subcontractors. HIPAA also requires covered entities to provide individuals with certain rights with respect to their PHI, and requires covered entities to enter into a written business associate contract or other arrangement with the business associate that establishes specifically what the business associate has been engaged to do and requires the business associate to comply with the requirements of HIPAA.
Paragraph 154 · 40% changed Every version of it
Our international sales are subject to higher credit risks than sales in the U.S. Many of our distributors are small and may not be well capitalized. Payment terms are relatively long. The European hospitals tend to be significantly slower in payment which has resulted in and may continue to result in an increase to our days sales outstanding from previous years. Our prices to our international distributors, outside of Europe, for products shipped to the customers from the U.S., Costa Rica or Mexico are generally denominated in U.S. dollars, but their resale prices are set in their local currency. A decline in the value of the local currency in relation to the U.S. dollar has in prior years adversely affected and may in future years adversely affect their ability to profitably sell in their market the products they buy from us, and has in prior years adversely affected and may in future years adversely affect their ability to make payment to us for the products they purchase. Legal recourse for non-payment of indebtedness may be uncertain. These factors all contribute to a potential for credit losses.
Paragraph 29 · 39% changed Every version of it
The ability of the FDA, foreign regulatory authorities and notified bodies to review and approve or certify new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency's ability to hire and retain key leadership and other personnel and accept the payment of user fees, and other events that may otherwise affect the government's ability to perform routine functions. Average review times at the FDA, other government agencies, foreign regulatory authorities and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA’s ability to conduct routine activities. If a prolonged government shutdown occurs, or if funding shortages, policy modifications, staffing limitations or similar factors hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other such regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Paragraph 179 · 39% changed Every version of it
We have additional production facilities outside the U.S. to reduce labor costs. We intend to continue to expand our marketing and distribution capability, which may include external expansion through acquisitions both in the U.S. and foreign markets. The expansion of our marketing, distribution and product offerings both internally and through acquisitions or by contract may place substantial burdens on our management resources and financial controls. Decentralization of assembly and manufacturing could place further burdens on management to manage those operations and maintain efficiencies and quality control.

MD&A

124 paragraphs · 24 new · 46 reworded · 16 gone · 10-K Feb 19, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 100 · 49% changed
(1) During 2022, 2025, we borrowed an aggregate of $1.7 billion under refinanced the Senior Secured existing Term Loan A and the existing Revolving Credit Facilities contained in the Credit Agreement to partially finance our acquisition of Smiths Medical Facility (see Note 13: 12: Long-Term Obligations to our accompanying consolidated financial statements for additional information). The proceeds are net of $37.8 million in payments of lender debt issuance costs. represent the incremental borrowings resulting from the refinancing.
Paragraph 70 · 45% changed
Funds generated from operations are held in cash and cash equivalents and investment securities. equivalents. During 2024, 2025, our cash and cash equivalents and short-term investment securities increased decreased by $53.8 $0.6 million from $254.7 million at December 31, 2023 to $308.6 million at December 31, 2024. 2024 to $308.0 million at December 31, 2025. This increase slight decrease was primarily due to cash generated from operations. operations offset by principal payments made during 2025 consisting of (i) $47.8 million payment on our Term Loan A and Term Loan B during the first quarter of 2025 (ii) $200.0 million of the $209.5 million received in cash consideration for the sale of a 60% interest in our IV Solutions business used to pay down a portion of our Term Loan A during the second quarter of 2025 (iii) $25.0 million payment on Term Loan B during the third quarter of 2025 and (iv) $30.0 million payment on Term Loan B during the fourth quarter of 2025.
Paragraph 34 · 41% changed
The increase in gross margin in 2024, 2025, as compared to 2023, 2024, was primarily driven by the impact of the sale of a 60% interest of our IV Solutions business on May 1, 2025, which is a lower supply chain costs due to synergies and freight rates, margin business. Gross margin also increased as a result of price increases, reduced spend on quality remediation activities and the impact of foreign exchange rate changes which was rates, lower supply chain costs and the realization of integration synergies. These improvements were partially offset by lower manufacturing absorption and higher inventory write-offs. an increase in IEEPA tariff costs of $25.7 million in 2025.
Paragraph 56 · 37% changed
In 2024, other miscellaneous (expense) income, net primarily includes $2.6 million in fees associated with our accounts receivable purchase program with BMO Bank N.A. ("BMO") (see Note: 18 Note 16: Accounts Receivable Purchase Program). In 2023, other miscellaneous (expense) income, net primarily includes $3.7 million in fees related to our accounts receivable purchase program (see Note 18: Accounts Receivable Purchase Program) mostly offset by a business interruption gain recognized upon receipt of insurance proceeds. We received total insurance recoveries for property damage and business interruption of $3.1 million, $2.6 million of which was related to insurance proceeds for business interruption included within other miscellaneous (expense) income, net.
Paragraph 97 · 36% changed
(4) Proceeds from the sale of our investment securities will vary based on the maturity dates of the investments. In 2022, proceeds from sale of investment securities includes $19.0 million received from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.
Paragraph 65 · 35% changed
The effective tax rate in 2022 2023 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, income, state income taxes, section 162(m) excess compensation, FDII, global intangible low-taxed income ("GILTI") and tax credits. The effective tax rate during 2022 included a tax benefit of $4.2 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The effective tax rate during 2022 also included a $0.0 million tax impact of the revaluation of contingent consideration of $6.8 million.
Paragraph 87 · 32% changed
In 2015, the Italy Medical Device Payback ("IMDP") was enacted in Italy,which Italy, which requires medical device companies to make payments to the Italian government if Italy's medical device expenditures for certain years exceeded annual regional expenditure ceilings. Since its enactment, the legislation has been subject to appeals in the Italian court system. In the third quarter of 2024, Italy's Constitutional Court issued two judgments, one of which confirmed the legitimacy of the legislation on the IMDP. However, litigation proceedings are still pending and In September 2025, the ultimate resolution remains unknown. As of December 31, 2024, we have accrued $23.9 million for potential payments related Italian government enacted a law that allows medical device companies to the IMDP, which is classified within our accrued liabilities. Given the uncertainty regarding this legislation and its enforcement, the timing and amount of payments could ultimately differ from our current expectations. settle certain
Paragraph 5 · 32% changed
We In recent years, we have experienced experienced, and may continue to experience experience, significant impacts to our business as a result of global economic challenges, resulting from, among other events, health pandemics and geopolitical conflicts. These impacts, conflicts which negatively impacted our gross profit margin during 2023 and 2022, include the impact of rising inflation, have resulted in fluctuating inflation rates, especially with respect to freight costs driven by higher fuel prices, increased cost and shortages of raw materials, and supply chain disruptions. While we expect the pressure disruptions, higher interest rates, volatility on the supply chain to lessen foreign currency exchange rates, and inflation to continue to subside, freight costs are expected to remain subject to volatility in the market. driven by higher fuel prices.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A306 words changed in this paragraph; it is 32% similar to last year's version.
Consolidated SG&A expenses decreased slightly in 2023, 2025, as compared to 2022, 2024, primarily due to decreases a decrease of $7.5 $9.8 million in depreciation and amortization, $4.8 $5.9 million in dealer fees, $3.9 million of office expenses, bad debt and $2.6 million of IT expenses. The overall decreases were mostly offset by increases of $7.8 warranty expense, and $5.5 million in compensation costs, $5.2 million in commissions, $3.5 costs which when combined with other smaller category decreases, were partially offset by an increase of $8.3 million in stock based compensation, compensation and $1.3 $4.9 million in sales and marketing expenses. professional services. Depreciation and amortization expense decreased in 2023 as primarily due to the trademark intangible recognized as part disposal of certain assets related to the January 2022 Smiths Medical acquisition had sale of a useful life 60% interest of six months our IV Solutions business (see Note 3: Assets Held For Sale and was fully amortized in 2022. Dealer fees Disposal of Business to our accompanying consolidated financial statements). Bad debt expense is adjusted quarterly, if deemed necessary, based on an assessment of our accounts receivables and our expectations regarding the collectability of those accounts. Warranty expense decreased due to a decrease in revenues the release of reserves related to distributors. Office certain products and IT expenses decreased based on current operating needs. lower warranty estimated reserve due to lower warranty claims expected. Compensation costs increased decreased primarily due to an increase in cash incentive compensation and employee benefits. Commissions increased primarily due to sales performance in 2023 measured against preset sales targets as compared to sales performance achieved against targets service fee income recorded in the comparable 2022 period. same line as the related personnel expenses for services provided to the joint venture (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements). Stock based compensation increased due to an increase a change in the fair value probability of amounts awarded in 2023 over the fair value of the awards in 2022. Sales and marketing expenses meeting certain financial targets related to a performance equity award. Professional services increased primarily due to an increase in trade show, conference, higher costs related to the use of third-party service providers supporting various projects and related expenses. initiatives.

Source: Item 7, 10-K 0000883984-26-000008 vs Item 7, 10-K 0000883984-25-000007

Risk Factors294 words changed in this paragraph; it is 58% similar to last year's version.
At December 31, 2024 and 2023, we had $308.6 million and $254.7 million of cash, cash equivalents and investment securities on hand, respectively, which was significantly less in each case than the balances maintained prior to the Smiths Medical acquisition. Although our management believes that we continue to have sufficient access to cash to meet our business objectives and capital needs, we currently have a decreased availability of cash, cash equivalents and investment securities and expect to continue to have such decreased availability of cash for the foreseeable future which could constrain our ability to grow our business. Furthermore, in In connection with the Smiths Medical transaction and the payment of the cash consideration, transaction, we entered into Senior Secured our Existing Credit Facilities (the "Senior Secured Agreement with Wells Fargo Bank and certain other financial institutions to refinance the Term Loan A and the existing Revolving Credit Facilities") Facility under the Credit Agreement dated as of $2.2 billion consisting January 6, 2022 (as amended by Amendment No. 1, dated as of October 5, 2022, the "Existing Credit Agreement," and as further amended by the Amendment, the "Amended Credit Agreement"), which resulted in us incurring additional borrowing costs. In October 31, 2025, we amended our Existing Credit Agreement to refinance our existing Term Loan A and Revolving Credit Facilities. The amended credit facility includes a new five-year term loan A facility of $850.0 million, a term loan B facility of $850.0 $750.0 million (the "Term Loan A"), and a new five-year revolving credit facility of $500.0 million. million (the "Revolving Credit Facility"). The proceeds from the new Term Loan A were primarily used by the lenders to (i) directly repay in full the $559.7 million of outstanding principal of the existing Term Loan A and (ii) directly repay $190.0 million of the outstanding balance of the Term Loan B under the Existing Credit Agreement. As a result of entering into the Senior Secured Credit Facilities, amended credit facility, we incurred additional borrowing costs. At December 31, 2024, 2025, our long-term debt outstanding was $1.6 $1.3 billion. Our more leveraged financial position following the Smiths Medical transaction could make us more vulnerable to general economic downturns and industry conditions, and place us at a competitive disadvantage relative to our competitors. In the event that we do not have adequate capital to maintain or develop our business and need to seek additional financing, additional capital may not be available to us on a timely basis, on favorable terms, or at all. Moreover, our Senior Secured New Credit Facilities (defined below) have certain restrictions that may limit how we operate our business, including our ability to engage in certain transactions and incur additional indebtedness, and our business may be materially and adversely affected if these restrictions prevent us from implementing our business plan. See “Business and Operating Risks - The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies.”

Source: Item 1A, 10-K 0000883984-26-000008 vs Item 1A, 10-K 0000883984-25-000007

Accounting Policies160 words changed in this paragraph; it is 36% similar to last year's version.
Certain reclassifications have been made to the prior year financial statements and footnotes to conform to the presentation used in the current year. In On the consolidated statements balance sheet, we combined prepaid income taxes with the "prepaid expenses and other current assets" line item. On the consolidated statement of cash flows, we reclassified bond premium amortization to other. The reclassification had no impact on cash flows from operating activities as previously reported. combined provision for doubtful accounts, provision for warranty, returns and field action, and usage of spare parts with the "other" line item. In Note 14: Income Taxes, 10: Prepaid Expenses and Other Current Assets we reclassified certain provision (benefit) for income combined deferred tax charge, foreign exchange contracts, and VAT/GST receivable with the "other" line item. In Note 11: Accrued Liabilities we combined operating lease liability, restructuring accrual, accrued sales taxes and tax asset categories. other taxes, accrued freight, accrued audit and professional services, distribution fees, warranties and returns, legal accrual, defined benefit plan, foreign exchange forward contracts, and accrued interest with the "other" line item. These reclassifications were made to conform to current year presentation and had no impact on the consolidated statement reported results of operations and consolidated balance sheets. operations.

Source: Item 8, Note 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000883984-26-000008 vs Item 8, Note 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000883984-25-000007

Legal Proceedings101 words changed in this paragraph; it is 64% similar to last year's version.
In 2015, legislation was enacted in Italy which requires medical device companies to make payments to the Italian government if Italy's medical device expenditures for certain years exceeded annual regional expenditure ceilings. Since its enactment, the legislation has been subject to appeals in the Italy court system. In the third quarter of 2024, Italy's Constitutional Court issued two judgments, one of which confirmed the legitimacy of the legislation on the Italy Medical Device Payback ("IMDP"). However, litigation proceedings are still pending IMDP. In September 2025, the Italian government enacted a law that allows medical device companies to settle certain historical periods (2015-2018) for 25% of the original assessed value. During the third quarter of 2025, we settled the liability related to the 2015-2018 historical periods and the ultimate resolution remains unknown. paid $2.5 million. Additionally, we recorded a release of $3.8 million in previously established reserves. The timing and amount release is included in total revenues in our consolidated statements of payments could ultimately differ from our current expectations (see operations. See Note 12: 11: Accrued Liabilities and Other Long-Term Liabilities for details on amounts accrued for potential payments related to the IMDP). IMDP.

Source: Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0000883984-26-000008 vs Item 3, via Note 16 – COMMITMENTS AND CONTINGENCIES, 10-K 0000883984-25-000007

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ICUI's Risk Factors and MD&A, 10-K Feb 19, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
terms that are less favorable to us. Any inability of current and/or potential customers to pay us for our products or any demands by suppliers for different payment terms may adversely affect our earnings and cash flow.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
We derive a significant portion of our revenues from non-U.S. sales and from products manufactured at our non-U.S. facilities which are then imported to the U.S. We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade tensions.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
The imposition of tariffs by the U.S. government and retaliatory tariffs imposed by other foreign governments is expected to increase our costs. Where possible, we may address increasing supply chain costs in pricing; however, we operate to a large extent under long-term contracts whereby pricing is fixed for a set period of time. The tariffs as currently implemented are likely to have a material impact on our business, financial condition and results of operations; however, the extent to which the imposition of tariffs, possible delays and exemptions may have a material impact remains fluid.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
Additionally, the imposition of higher tariffs could undermine the competitiveness of a U.S. based company in the global market and could result in termination of orders by customers, lower demand for products and the loss of market share.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
A meaningful portion of our global revenues is from products manufactured in our Costa Rica and Mexico manufacturing facilities which are then imported into the U.S. We expect revenues from goods manufactured in Costa Rica and Mexico and imported to the U.S. to remain a significant portion of our revenues for the foreseeable future.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
The U.S. administration has continued to engage in trade discussions and impose tariffs on imports from other countries. Certain of these tariffs have been subsequently paused or modified, and the situation remains highly fluid. For example, most recently, on July 31, 2025, the U.S. announced that the 10% baseline reciprocal tariff on imports from all countries would be raised to 15% for certain countries, including Costa Rica. As to the majority of products manufactured in our Mexico facilities, these are currently exempted from tariffs under the United States-Mexico-Canada Agreement ("USMCA"). If, however, the USMCA exemptions were eliminated in the future, our tariff expense for products manufactured in Mexico would increase substantially.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
In September 2025, the U.S. Commerce Department ("the Department") initiated a national security investigation into imports of medical consumables and equipment under Section 232 of the Trade Expansion Act (the "Act"). The Act allows the President to negotiate tariffs to promote international trade. Section 232 of the Act specifically grants the President the authority to impose tariffs if the Department determines imports threaten U.S. national security. The Department has 270 days to deliver its policy recommendations to the President, who then has up to 90 days to decide on potential action and 15 days to implement it. If the probes conducted determine these imports, which comprise the vast majority of our product portfolio, pose a national security risk, it could result in potential tariffs imposed in addition to the country-based tariffs and/or could reduce the benefits we receive from currently available exemptions such as the USMCA.
Read it in 10-K Feb 19, 2026 at sec.gov
Show the other 65
AddedRisk Factors
These actions have resulted, and are expected to further result, in retaliatory measures on U.S. goods by other foreign governments. If maintained, these recently announced tariffs, and the potential escalation of trade disputes could pose a risk to our business that could further affect our financial condition or results of operations and/or cash flows, as well as, our long-term investment strategies. The extent and duration of the tariffs and the resulting impact on general economic conditions and on our business are uncertain and are expected to be impacted by various factors, such as negotiations between U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that already exist or may be granted, availability and cost of alternative sources of our products and materials, and our ability to offset the effects of any tariffs that might be imposed.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
In addition, modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
are necessary. We have modified certain of our products subsequent to obtaining 510(k) clearance, and have determined based on our review of the applicable FDA guidance that in these instances new 510(k) clearances or pre-market approvals were not required. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMAs for modifications to our products or any other product for which we may obtain 510(k) clearance in the future, and for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. On April 4, 2025, we received a warning letter from the FDA regarding certain modifications we made to our cleared MedFusion™ Model 4000 Syringe Infusion Pump and CADD™ Solis VIP Ambulatory Infusion Pump, and since then we are working closely with the FDA to resolve all concerns identified in such warning letter, including the filing of new clearances for next generation MedFusion™ and a refreshed CADD™ Solis device (which are currently under review by the FDA), and though we believe we will be able to ultimately close out this warning letter, there is no guarantee that we will be able to do so in a timely manner, or that we will not receive similar notices in the future.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
Foreign data protection laws, including the European Union General Data Protection Regulation (the "EU GDPR") and the United Kingdom General Data Protection Regulation (the "UK GDPR") (the EU GDPR and UK GDPR together referred to as the "GDPR", may also apply to health-related and other personal data obtained outside of the U.S. or in the context of our establishments outside of the U.S.. The GDPR imposes strict requirements for processing the personal data of individuals within the EEA and the UK or in the context of our activities within the EEA and the UK, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose,
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedRisk Factors
applicable rules or regulations could lead to penalties and adversely impact our reputation, customer attraction and retention, access to capital and employee retention. Such sustainability and ESG matters may also impact our suppliers and customers, which may augment or cause additional impacts on our business, financial condition, or results of operations.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
For example, in September 2019, the FDA issued revised final guidance describing an optional "safety and performance based" pre-market review pathway for manufacturers of "certain, well-understood device types" to demonstrate substantial equivalence under the 510(k) clearance pathway by demonstrating that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the "safety and performance based pathway" and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
The rules applicable in Great Britain differ from the EEA as a result of Brexit. On June 26, 2022, the Medicines and Healthcare Products Regulatory Agency (“MHRA”) published its response to a 10-week consultation on the future regulation of medical devices in the United Kingdom (“UK”). The MHRA proposes amendments to the UK Medical Devices Regulations 2002 (which are based on EU legislation, primarily the EU Medical Devices Directive), in particular to create new access pathways to support innovation, create an innovative framework for regulating software and artificial intelligence as medical devices, reform in vitro diagnostic regulation, and foster sustainability through the reuse and remanufacture of medical devices. The MHRA has stated that it continues its intention to implement the proposals from such consultation through secondary legislation. In addition, on November 14, 2024, the MHRA launched a new consultation on proposals to update the regulatory framework for medical devices in Great Britain, covering four topics, namely (1) a new international reliance scheme to enable swifter market access for certain devices that have already been approved in a comparable regulator country; (2) the new UK Conformity Assessed (“UKCA”) mark and, in particular, proposals to remove the requirement to place such UKCA marking on devices; (3) conformity assessment procedures for in vitro diagnostic devices; and (4) maintaining in UK law certain pieces of “assimilated” EU law which are due to sunset in 2025. The MHRA consultation was opened until January 5, 2025, and it is expected that secondary legislation implementing the proposals would be introduced in 2025. The divergence of the new UK rules from EU law could adversely affect or delay our ability to obtain approval for our products in the UK, which could adversely affect our ability to grow our business. See “Part 1, Item 1. Government Regulation - Regulation of Medical Devices in the European Union – Brexit and the UK Regulatory Framework.”
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a further discussion of the financial impact of exchange rate fluctuations on our results of operations. Fluctuations in currency exchange rates are caused by a number of factors that are beyond our control, including a country’s political and economic policies, inflationary conditions, disruptions in the financial markets, and global economic and geopolitical conditions.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
The Smiths Medical acquisition has resulted in significant growth in our personnel and operations, adding approximately 6,700 employees to our headcount at the time of acquisition. Our total headcount as of December 31, 2024 was approximately 15,000 employees. We have incurred and continue to incur significant expenditures and the allocation of management time to assimilate the Smiths Medical employees in a manner that preserves the key aspects of our corporate culture, including a focus on strong customer satisfaction, but there can be no assurance that we will be successful in our efforts. If we do not effectively integrate, train and manage our combined employee base and maintain strong customer
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
We As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we operate our business, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Specifically, this final rule, The QMSR, which replaced the FDA expects to go into effect on February 2, 2026, establishes FDA’s former Quality System Regulation, sets forth the “Quality Management System Regulation,” (“QMSR”), which FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
A decline in the value of the local currency in relation to the U.S. dollar has in prior years adversely affected and may in future years adversely affect their ability to profitably sell in their market the products they buy from us, and has in prior years adversely affected and may in future years adversely affect their ability to make payment to us for the products they purchase.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
For example, in June 2024, Smiths Medical ASD initiated Class 1 recalls with respect to certain tracheostomy tube kits, and, in May 2024, Smiths Medical ASD initiated Class 1 recalls for certain paraPAC plus ventilators, and in April 2025 and February 2025, we initiated Class 1 recalls for certain CADD Solis ambulatory infusion pumps and ProPort venous access systems and catheters, respectively.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
While we have not previously breached and are not currently in breach of these or any other covenants contained in our credit agreement, our ability to comply with these covenants may be affected by events beyond our control, including health crises and global pandemics, other geopolitical events, supply chain interruptions or general economic environment, including high inflation and interest rates.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
For the Smiths Medical acquisition, we used a significant portion of our cash on hand and incurred a substantial amount of debt to finance the cash consideration portion and certain other amounts paid in connection with the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If our manufacturing facilities or those of any of our component suppliers are found to be in violation of applicable laws and regulations, or we or our suppliers have significant noncompliance issues or fail to timely and adequately respond to any adverse inspectional observations or product safety issues, or if any corrective action plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA or foreign regulatory authorities could take enforcement action, including any of the following sanctions:
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
This evolution may create uncertainty in our business, affect our or our collaborators', service providers' and contractors' ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If the cost of key components or raw materials increases and we are unable to fully recover those increased costs through price increases or offset these increases through other cost reductions, we could experience an adverse effect on our results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If we do not achieve significant sales of these new/transitioned products, it might be necessary for us to recognize an impairment charge for the value of the production tooling because its costs may not be recovered through production of saleable product, which could adversely affect our financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
In particular, we We expect the DPF Adequacy Decision existing legal complexity and uncertainty regarding international personal data transfers to be challenged continue, and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
There can also be no assurance that our and our third-party service providers’, strategic partners’, contractors’, consultants’, CROs’ and collaborators’ cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
While we may from time to time engage in various initiatives (including but not limited to voluntary disclosures, policies or goals) to improve our ESG profile or respond to certain stakeholder expectations, we cannot guarantee that these initiatives will have the desired effect.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Such laws and regulations will be are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Increased tariffs could require us to increase our prices, which likely could decrease demand for our products, and in certain many cases we may be unable to pass along increased costs to our customers if they are under long-term fixed price contracts.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
The U.S. administration has continued to engage in trade discussions and impose tariffs on imports from other countries. Certain of these tariffs have been subsequently paused or modified, and the situation remains highly fluid. For example, on July 31, 2025, the U.S. announced that the 10% baseline reciprocal tariff on imports from all countries would be raised to 15% for certain countries, including Costa Rica. More recently, the U.S. administration threatened to impose additional tariffs on European allies as a penalty for the Greenland dispute. In response, the European Union prepared a list of retaliatory tariffs; subsequently, the U.S. withdrew the proposed tariffs following diplomatic discussions.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
The majority of our global revenues are from products manufactured in our Costa Rica and Mexico manufacturing facilities and imported into the U.S. Currently the vast majority of products manufactured in our Mexico facilities are exempted from tariffs under the United States-Mexico-Canada Agreement ("USMCA"). If, however, the USMCA exemptions were eliminated in the future, our tariff expense for products manufactured in Mexico would increase substantially. The tariffs as currently implemented are likely to have a material impact on our business, financial condition and results of operations through the incurrence of additional costs; however, the extent to which the imposition of tariffs, possible delays and exemptions may have a material impact remains fluid. During 2025, we incurred $33.6 million in incremental reciprocal tariffs as a result of the tariffs imposed by the U.S. Administration in 2025, of which $7.9 million was capitalized and $25.7 million was expensed.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
In September 2025, the U.S. Commerce Department (the "Department") initiated a national security investigation into imports of medical consumables and equipment under Section 232 of the Trade Expansion Act (the "Act"). The Act allows the President to negotiate tariffs to promote international trade. Section 232 of the Act specifically grants the President the authority to impose tariffs if the Department determines imports threaten U.S. national security. The Department has 270 days to deliver its policy recommendations to the President, who then has up to 90 days to decide on potential action and 15 days to implement it. If the probes conducted determine these imports, which comprise the vast majority of our product portfolio, pose a national security risk, it could result in potential tariffs imposed in addition to the country-based tariffs and/or could reduce the benefits we receive from currently available exemptions such as the USMCA.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On April 24, 2025, pursuant to a purchase agreement (the "Agreement") with Otsuka Pharmaceutical Factory America, Inc. a Delaware corporation ("OPF") (described in Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements), we completed the formation of ICU Medical Pearl LLC (n/k/a Otsuka ICU Medical LLC (the "joint venture")) and transferred the assets, liabilities and operations that comprise our IV Solutions product line to the joint venture. At the closing of the transaction on May 1, 2025, under the Agreement, we sold a 60% interest in the joint venture to OPF. The total sales price, inclusive of our final price adjustments, was $211.2 million, of which we used $200.0 million of the proceeds from the sale to pay down a portion of our outstanding Term Loan A (as defined below) long-term debt during the second quarter of 2025.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. The presentation of revenues on a constant currency basis is a non-GAAP financial
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
Vital Care revenue decreased in 2025, as compared to 2024, primarily due to lower IV Solutions sales of $213.9 million as a result of the sale of a controlling ownership interest in our IV Solutions business on May 1, 2025 (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements).
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
Consolidated SG&A expenses decreased in 2025, as compared to 2024, primarily due to a decrease of $9.8 million in depreciation and amortization, $5.9 million in bad debt and warranty expense, and $5.5 million in compensation costs which when combined with other smaller category decreases, were partially offset by an increase of $8.3 million in stock based compensation and $4.9 million in professional services. Depreciation and amortization expense decreased primarily due to the disposal of certain assets related to the sale of a 60% interest of our IV Solutions business (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements). Bad debt expense is adjusted quarterly, if deemed necessary, based on an assessment of our accounts receivables and our expectations regarding the collectability of those accounts. Warranty expense decreased due to the release of reserves related to certain products and lower warranty estimated reserve due to lower warranty claims expected. Compensation costs decreased primarily due to service fee income recorded in the same line as the related personnel expenses for services provided to the joint venture (see Note 3: Assets Held For Sale and Disposal of Business to our accompanying consolidated financial statements). Stock based compensation increased due to a change in the probability of meeting certain financial targets related to a performance equity award. Professional services increased primarily due to higher costs related to the use of third-party service providers supporting various projects and initiatives.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
Additionally, interest expense during 2025 includes the interest accretion on an unfavorable contract loss provision and a loss on debt extinguishment due to a debt refinancing which we completed in October 2025, (see Note 12: Long-Term Obligations in our accompanying consolidated financial statements).
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
The interest expense component decreased in 2025, as compared to 2024, primarily due to decrease in the applicable SOFR reference rate and due to lower obligation principal balances. During 2025 we prepaid $35.0 million on our Term Loan B in March 2025, $200.0 million on our Term Loan A in May 2025 using proceeds from the sale of a 60% interest of our IV Solutions business, $25.0 million on our Term Loan B in September 2025, and $30.0 million on our Term Loan B in December 2025. Additionally, the October 2025 debt refinance reduced borrowing costs in the last part of the year as $190.0 million of the lower rate Term Loan A issuance was used to settle a portion of the higher rate Term Loan B in a cashless roll.
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedMD&A
catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We also continue to expect higher interest rates and volatility in foreign currency rates due to the strengthening of the U.S. dollar against most global currencies. Our 2024, 2023 and 2022 financial results were negatively impacted by foreign exchange losses and our results of operations may continue to be impacted in the future.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
More recently, in January 2025, the current administration issued executive orders imposing tariffs on imported goods from Canada, Mexico, and China. In response, Canada announced similar tariffs on U.S. imports. A meaningful portion of our global revenues are from products manufactured in our Mexico manufacturing facilities and imported into the U.S. In addition, Canada is our second largest country in terms of revenue and the vast majority of products sold in Canada are imported from the U.S. The 25% tariff levied on all goods shipped from Mexico to the U.S., combined with the 25% tariff on products shipped from the U.S. to Canada could potentially have a meaningful impact to our costs and any further trade war escalation could increase that impact.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Vital Care revenue decreased in 2023, as compared to 2022, primarily due to lower sales volume of IV Solutions which was impacted by supply disruptions related to finished good products purchased from third-party manufacturers and lower sales volume for products acquired from Smiths Group plc ("Smiths") due to backorder recovery in 2022.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
On January 6, 2022, we acquired Smiths Medical. We financed the $1.9 billion cash portion of the purchase price at closing with a combination of proceeds from the Senior Secured Credit Facilities and our cash and cash equivalents. See Note 2: Acquisitions and Note 13: Long-Term Obligations in our accompanying consolidated financial statements for additional information.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
(2) Our business acquisitions will vary from period to period based upon our current growth strategy and our ability to execute on desirable target companies. In 2022, we acquired Smiths Medical. The cash consideration for the transaction was $1.9 billion, which was financed with existing cash balances and borrowings under the Credit Agreement. Acquired cash was $78.8 million.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
(3) Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and changes in our investment strategy. Our investment policy allows for the purchase of securities with final maturities in excess of one year. If cash is not needed for known future transactions our investment strategy takes advantage of the long-term securities with higher yields. Typically, our longer term securities have maturities up to three years.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The application of the acquisition method of accounting for business combinations requires the use of significant estimates, assumptions and judgments in the determination of the estimated fair value of assets acquired and liabilities assumed in order to properly allocate the purchase price at the acquisition date.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Although we believe the estimates, assumptions and judgments we have made are reasonable, they are based in part on historical experience, industry data, information obtained from the management of the acquired companies and assistance from independent third-party appraisal/valuation firms, and are inherently uncertain.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
Percentage of Revenues 2025 2024 2023 2022 Total revenues 100% 100% 100% Gross profit 37% 35% 33% 31% Selling, general and administrative expenses 27% 28% 27% 27% Research and development expenses 4% 4% 4% Restructuring, strategic transaction and integration expenses 3% 3% 2% 3% Change in fair value of contingent earn-out —% (1)% —% (1)% Total operating expenses 35% 34% 32% 33% Income from operations 2% 1% 1% (2)% Interest expense, net (4)% (4)% (3)% (4)% Other expense, net —% (1)% —% Gain on sale of business 2% —% Loss —% Income (Loss) before income taxes and equity in losses of unconsolidated affiliates —% (4)% (3)% (5)% Provision (benefit) (Provision) benefit for income taxes —% 2% (2)% (2)% Net loss income (loss) from consolidated affiliates —% (6)% (1)% (3)% Equity in losses of unconsolidated affiliates —% —% —% Net income (loss) —% (6)% (1)%
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
We In recent years, we have experienced experienced, and may continue to experience experience, significant impacts to our business as a result of global economic challenges, resulting from, among other events, health pandemics and geopolitical conflicts. conflicts which have resulted in fluctuating inflation rates, especially with respect to increased cost and shortages of raw materials, supply chain disruptions, higher interest rates, volatility on foreign currency exchange rates, and freight costs driven by higher fuel prices.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The changes in operating assets and liabilities included Offsetting these amounts was a $201.1 $26.3 million increase in inventories, a $21.3 $11.0 million increase in prepaid expenses and other current assets, a $7.0 million increase in other assets, a $55.8 $37.0 million decrease in accrued liabilities, $66.7 and $24.8 million in net changes in income taxes, including excess tax benefits and deferred income taxes, and a $19.2 million increase in accounts receivable. taxes.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Due to the weight of objectively verifiable negative evidence, the Company recorded a change to the valuation allowance of $81.7 million tax expense and $3.9 million foreign currency translation and derivative instrument adjustments against certain U.S. federal and state deferred tax assets assets, resulting in a $8.7 million tax expense and $2.8 million foreign currency translation and derivative instrument adjustments, for the tax years ending December 31, 2024. 2025.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The Credit Agreement provides for amended credit facility includes a new five-year term loan A facility of $850.0 $750.0 million (the "Term Loan A"), a seven-year term loan B facility of $850.0 million (the "Term Loan B") and a new five-year revolving credit facility of $500.0 million (the "Revolving Credit Facility") (collectively, the "Senior Secured Credit Facilities"). Facility").
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, $ change % change $ change % change 2025 2024 2023 2022 2025 over 2024 2024 over 2023 2023 over 2022 Consumables revenue (GAAP) $ 1,038.9 1,109.2 $1,038.9 $969.1 $975.0 $ 70.3 6.8% $ 69.8 7.2% $ (5.9) (0.6)% Impact of foreign exchange rate changes (6.6) 2.8 $4.0 Consumables revenue on a constant currency basis (non-GAAP) $ 1,041.7 $973.1 1,102.6 $1,041.7 $ Change in constant currency $ 72.6 $(1.9) 63.7 $72.6 % Change in constant currency 7.5 6.1 % (0.2)% 7.5%
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, $ change % change $ change % change 2025 2024 2023 2022 2025 over 2024 2024 over 2023 2023 over 2022 Infusion Systems (GAAP) $ 652.4 684.2 $652.4 $629.0 $617.4 $ 31.8 4.9% $ 23.4 3.7% $ 11.6 1.9% Impact of foreign exchange rate changes (1.3) 20.3 $10.5 Infusion Systems on a constant currency basis (non-GAAP) $ 672.7 $639.5 682.9 $672.7 $ Change in constant currency $ 43.7 $22.1 30.5 $43.7 % Change in constant currency 6.9 4.7 % 3.6% 6.9%
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The Additionally, the effective tax rate in 2024 2025 included a tax benefit of $10.1 $7.1 million primarily related to unrecognized tax benefits released as a result of the expiration of the statute of limitations offset by a tax expense of $81.7 million related to a valuation allowance against certain U.S. federal and state deferred tax assets. limitations.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
In 2024, 2025 we incurred $40.2 $36.5 million in strategic transaction and integration expenses primarily related to consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022. 2022, and transaction costs related to the sale of a 60% interest of our IV Solutions business in the second quarter of 2025.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The foreign exchange losses gains, net in 2024 2025 were primarily related to the strengthening weakening of the U.S. dollar relative to certain foreign currencies, including the Euro and British Pound, partially offset by the weakening of the U.S. dollar relative to the Mexican peso and Argentine peso. Peso.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
During 2024, 2025, our cash and cash equivalents and short-term investment securities increased decreased by $53.8 $0.6 million from $254.7 million at December 31, 2023 to $308.6 million at December 31, 2024. 2024 to $308.0 million at December 31, 2025.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The primary drivers for the net decrease in accrued liabilities was primarily due to payments for field corrective actions, operating lease liabilities and distributor rebates as well as a decrease in deferred revenue offset partially by increases in accrued employee costs.
Read it in 10-K Feb 19, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.